OligoDOMTM: a T-cell response-enhancing platform applied to cancer immunotherapy
Combining oligoDOM™ and LNP-mRNA technologies offers a versatile platform that allows for efficient short neoepitope strings delivery. This approach represents a feasible, potentially effective strategy for personalized cancer immunotherapy.
Authors
- Elena Quaglino (ORCID: https://orcid.org/0000-0002-8151-9124)
- Judith del Campo (ORCID: https://orcid.org/0000-0002-4797-5898)
- Roberto Ruiu (ORCID: https://orcid.org/0000-0002-0431-2656)
- Dalil Hannani (ORCID: https://orcid.org/0000-0001-5097-1401)
- Elsa Nikly
- Séverine Valsesia (ORCID: https://orcid.org/0000-0002-4503-5202)
- Emilie Boucher (ORCID: https://orcid.org/0000-0002-9293-3232)
- Alexandre Le Vert (ORCID: https://orcid.org/0009-0008-1014-1858)
- Francesco Doro
- Antonella Iacoviello (ORCID: https://orcid.org/0000-0002-5851-6785)
- Federica Cavallo (ORCID: https://orcid.org/0000-0003-2047-1099)
- Florence Nicolas (ORCID: https://orcid.org/0000-0003-4404-7508)
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Institut polytechnique de Grenoble (FR)
- Centre National de la Recherche Scientifique (FR)
- Institut Pascal (FR)
- Université Clermont Auvergne (FR)
- VetAgro Sup (FR)
- Immunité et Cancer (FR)
- Translational Innovation in Medicine and Complexity (FR)
- Centre International de Recherche en Infectiologie (FR)
- Abivax (France) (FR)
- University of Turin (IT)
- Université Grenoble Alpes (FR)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-03-14
- DOI
- https://doi.org/10.3389/fimmu.2025.1549112
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Cancer Institute